COLLEGIUM PHARMACEUTICAL, INC (COLL) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does COLLEGIUM PHARMACEUTICAL, INC Do?
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. COLLEGIUM PHARMACEUTICAL, INC (COLL) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Joseph J. Ciaffoni and employs approximately 210 people, headquartered in Canton, Massachusetts. With a market capitalization of $1.1B, COLL is one of the notable companies in the Healthcare sector.
COLLEGIUM PHARMACEUTICAL, INC (COLL) Stock Rating — Reduce (April 2026)
As of April 2026, COLLEGIUM PHARMACEUTICAL, INC receives a Reduce rating with a composite score of 47.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.COLL ranks #2,407 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, COLLEGIUM PHARMACEUTICAL, INC ranks #297 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
COLL Stock Price and 52-Week Range
COLLEGIUM PHARMACEUTICAL, INC (COLL) currently trades at $35.47. The stock gained $0.22 (0.6%) in the most recent trading session. The 52-week high for COLL is $50.79, which means the stock is currently trading -30.2% from its annual peak. The 52-week low is $23.23, putting the stock 52.7% above its annual trough. Recent trading volume was 508K shares, suggesting relatively thin trading activity.
Is COLL Overvalued or Undervalued? — Valuation Analysis
COLLEGIUM PHARMACEUTICAL, INC (COLL) carries a value factor score of 76/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 18.83x, compared to the Healthcare sector average of 23.63x — a discount of 20%. The price-to-book ratio stands at 3.45x, versus the sector average of 2.75x. The price-to-sales ratio is 1.42x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, COLL trades at 6.77x EV/EBITDA, versus 6.34x for the sector.
Based on these multiples, COLLEGIUM PHARMACEUTICAL, INC appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.
COLLEGIUM PHARMACEUTICAL, INC Profitability — ROE, Margins, and Quality Score
COLLEGIUM PHARMACEUTICAL, INC (COLL) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 18.3%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 3.3% versus the sector average of -33.1%.
On a margin basis, COLLEGIUM PHARMACEUTICAL, INC reports gross margins of 58.7%, compared to 71.5% for the sector. The operating margin is 20.6% (sector: -66.1%). Net profit margin stands at 7.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 44.1% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
COLL Debt, Balance Sheet, and Financial Health
COLLEGIUM PHARMACEUTICAL, INC has a debt-to-equity ratio of 449.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.57x, suggesting adequate working capital coverage. Cash and equivalents stand at $150M.
COLL has a beta of 0.50, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for COLLEGIUM PHARMACEUTICAL, INC is 66/100, reflecting average volatility within the normal range for its sector.
COLLEGIUM PHARMACEUTICAL, INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, COLLEGIUM PHARMACEUTICAL, INC reported revenue of $734M and earnings per share (EPS) of $1.98. Net income for the quarter was $55M. Gross margin was 58.7%. Operating income came in at $154M.
In FY 2025, COLLEGIUM PHARMACEUTICAL, INC reported revenue of $781M and earnings per share (EPS) of $1.98. Net income for the quarter was $63M. Gross margin was 59.4%. Revenue grew 23.6% year-over-year compared to FY 2024. Operating income came in at $180M.
In Q3 2025, COLLEGIUM PHARMACEUTICAL, INC reported revenue of $209M and earnings per share (EPS) of $1.00. Net income for the quarter was $32M. Gross margin was 61.7%. Revenue grew 31.4% year-over-year compared to Q3 2024. Operating income came in at $62M.
In Q2 2025, COLLEGIUM PHARMACEUTICAL, INC reported revenue of $188M and earnings per share (EPS) of $0.38. Net income for the quarter was $12M. Gross margin was 57.6%. Revenue grew 29.4% year-over-year compared to Q2 2024. Operating income came in at $35M.
Over the past 8 quarters, COLLEGIUM PHARMACEUTICAL, INC has demonstrated a growth trajectory, with revenue expanding from $145M to $734M. Investors analyzing COLL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
COLL Dividend Yield and Income Analysis
COLLEGIUM PHARMACEUTICAL, INC (COLL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
COLL Momentum and Technical Analysis Profile
COLLEGIUM PHARMACEUTICAL, INC (COLL) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 6/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
COLL vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, COLLEGIUM PHARMACEUTICAL, INC (COLL) ranks #297 out of 838 stocks based on the Blank Capital composite score. This places COLL in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing COLL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full COLL vs S&P 500 (SPY) comparison to assess how COLLEGIUM PHARMACEUTICAL, INC stacks up against the broader market across all factor dimensions.
COLL Next Earnings Date
No upcoming earnings date has been announced for COLLEGIUM PHARMACEUTICAL, INC (COLL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy COLL? — Investment Thesis Summary
The quantitative profile for COLLEGIUM PHARMACEUTICAL, INC suggests caution. The value score of 76/100 suggests attractive pricing relative to fundamentals. Low volatility (stability score 66/100) reduces downside risk.
In summary, COLLEGIUM PHARMACEUTICAL, INC (COLL) earns a Reduce rating with a composite score of 47.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on COLL stock.
Related Resources for COLL Investors
Explore more research and tools: COLL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare COLL head-to-head with peers: COLL vs AZN, COLL vs SLGL, COLL vs VMD.